Meningiomas classified as grade 2 due to brain invasion alone have better progression-free survival than other atypical meningiomas.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Salem M Tos, Sofia Kollia, Georgios Mantziaris, Georgios A Maragkos, Carson Brantley, Jared H Chung, Maria-Beatriz Lopes, Ashok R Asthagiri
{"title":"Meningiomas classified as grade 2 due to brain invasion alone have better progression-free survival than other atypical meningiomas.","authors":"Salem M Tos, Sofia Kollia, Georgios Mantziaris, Georgios A Maragkos, Carson Brantley, Jared H Chung, Maria-Beatriz Lopes, Ashok R Asthagiri","doi":"10.1007/s11060-026-05783-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brain invasion (BI) was incorporated as a major criterion for grade 2 meningiomas in the 2016 WHO guidelines. However, its prognostic value remains controversial due to variability in surgical sampling and histopathologic interpretation, as well as BI may be the consequence of mechanical forces related more with the size of the tumor than the biologic presence of an innately more aggressive biologic lesion. Despite advances in molecular characterization of meningiomas, the relevance of BI as an independent prognostic indicator remains unresolved. We sought to determine whether BI alone, taken out of context of other parameters, particularly tumor size, truly represents a more aggressive standalone feature, by comparing time-to-progression (TTP) in atypical meningiomas classified as such due to BI alone versus other atypical meningiomas.</p><p><strong>Methods: </strong>A single-institutional retrospective cohort study of patients with resected meningiomas from 2003 to 2023 was performed. Pathology reports were reviewed and tumors were re-graded using current WHO criteria. Only WHO Grade 2 patients were included in the study. Patients were then divided into two cohorts: The BIOB (Brain Invasion Otherwise Benign) group and \"other criteria\" (OC) group. Primary outcome was TTR and association of factors with TTR were assessed using Cox regression.</p><p><strong>Results: </strong>131 patients with a mean age of 59.2 ± 15.9 years were included. Median (IQR) preoperative tumor volume was 34.3 cm<sup>3</sup> (16-57.9). Gross total resection was achieved in 69 (53%) tumors. 18 patients (14%) had adjuvant radiation. BI was noted in 78 (60%) patients, 45 (34%) of which were classified as BIOB. Mean radiographic follow-up was 74 ± 56 months. Progression was noted in 40 (31%) patients at a mean of 40 ± 39 months post-resection. Progression occurred in 17.8% of BIOB patients (8/45) and 37.2% of OC patients (32/86). Baseline demographic, radiologic, and treatment characteristics did not differ significantly between BIOB and OC groups (all P > 0.3). On univariate Cox regression, TTR was associated with the BIOB group (Hazard Ratio [HR] = 0.44, P = 0.036), GTR (HR = 0.29, P < 0.001), and residual volume (HR = 1.04, P = 0.002). On multivariable Cox regression, BIOB was associated with longer TTR (HR = 0.44, P = 0.041), when controlling for GTR and posterior fossa location.</p><p><strong>Conclusions: </strong>Atypical meningiomas secondary to brain invasion alone were associated with significantly longer TTR than tumors with other Grade 2 criteria. This was especially robust for larger BI-only tumors. Further research is needed to delineate if brain invasion should truly be a standalone criterion for Grade 2 classification.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"179 2","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569586/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-026-05783-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Brain invasion (BI) was incorporated as a major criterion for grade 2 meningiomas in the 2016 WHO guidelines. However, its prognostic value remains controversial due to variability in surgical sampling and histopathologic interpretation, as well as BI may be the consequence of mechanical forces related more with the size of the tumor than the biologic presence of an innately more aggressive biologic lesion. Despite advances in molecular characterization of meningiomas, the relevance of BI as an independent prognostic indicator remains unresolved. We sought to determine whether BI alone, taken out of context of other parameters, particularly tumor size, truly represents a more aggressive standalone feature, by comparing time-to-progression (TTP) in atypical meningiomas classified as such due to BI alone versus other atypical meningiomas.

Methods: A single-institutional retrospective cohort study of patients with resected meningiomas from 2003 to 2023 was performed. Pathology reports were reviewed and tumors were re-graded using current WHO criteria. Only WHO Grade 2 patients were included in the study. Patients were then divided into two cohorts: The BIOB (Brain Invasion Otherwise Benign) group and "other criteria" (OC) group. Primary outcome was TTR and association of factors with TTR were assessed using Cox regression.

Results: 131 patients with a mean age of 59.2 ± 15.9 years were included. Median (IQR) preoperative tumor volume was 34.3 cm3 (16-57.9). Gross total resection was achieved in 69 (53%) tumors. 18 patients (14%) had adjuvant radiation. BI was noted in 78 (60%) patients, 45 (34%) of which were classified as BIOB. Mean radiographic follow-up was 74 ± 56 months. Progression was noted in 40 (31%) patients at a mean of 40 ± 39 months post-resection. Progression occurred in 17.8% of BIOB patients (8/45) and 37.2% of OC patients (32/86). Baseline demographic, radiologic, and treatment characteristics did not differ significantly between BIOB and OC groups (all P > 0.3). On univariate Cox regression, TTR was associated with the BIOB group (Hazard Ratio [HR] = 0.44, P = 0.036), GTR (HR = 0.29, P < 0.001), and residual volume (HR = 1.04, P = 0.002). On multivariable Cox regression, BIOB was associated with longer TTR (HR = 0.44, P = 0.041), when controlling for GTR and posterior fossa location.

Conclusions: Atypical meningiomas secondary to brain invasion alone were associated with significantly longer TTR than tumors with other Grade 2 criteria. This was especially robust for larger BI-only tumors. Further research is needed to delineate if brain invasion should truly be a standalone criterion for Grade 2 classification.

2级脑膜瘤的无进展生存期优于其他非典型脑膜瘤。
背景:2016年世卫组织指南将脑侵犯(BI)作为2级脑膜瘤的主要标准。然而,由于手术取样和组织病理学解释的差异,其预后价值仍然存在争议,并且BI可能是与肿瘤大小相关的机械力的结果,而不是先天更具侵袭性的生物病变的生物学存在。尽管脑膜瘤的分子特征有所进展,但BI作为独立预后指标的相关性仍未得到解决。我们试图通过比较非典型脑膜瘤与其他非典型脑膜瘤的进展时间(TTP),在不考虑其他参数(特别是肿瘤大小)的情况下,确定单独BI是否真正代表了一种更具侵袭性的独立特征。方法:对2003年至2023年脑膜瘤切除术患者进行单机构回顾性队列研究。对病理报告进行了审查,并根据现行的世卫组织标准对肿瘤进行了重新分级。只有WHO 2级患者被纳入研究。然后将患者分为两组:BIOB(脑侵袭其他良性)组和“其他标准”(OC)组。主要终点为TTR,并使用Cox回归评估与TTR相关的因素。结果:131例患者入组,平均年龄59.2±15.9岁。术前肿瘤体积中位数(IQR)为34.3 cm3(16-57.9)。69例(53%)肿瘤全部切除。18例(14%)患者接受了辅助放疗。78例(60%)患者出现BI,其中45例(34%)为BIOB。平均随访时间为74±56个月。40例(31%)患者在术后平均40±39个月出现进展。17.8%的BIOB患者(8/45)和37.2%的OC患者(32/86)出现进展。基线人口统计学、放射学和治疗特征在BIOB组和OC组之间没有显著差异(P均为0.0.3)。单因素Cox回归分析显示,TTR与BIOB组相关(风险比[HR] = 0.44, P = 0.036), GTR相关(风险比[HR] = 0.29, P)。结论:单纯继发于脑侵犯的非典型脑膜瘤的TTR明显长于其他2级标准的肿瘤。对于较大的双侧肿瘤,这一点尤其明显。需要进一步的研究来描述脑侵犯是否真的应该作为2级分类的独立标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书